Positive 24-Week NTX-001 Data in NEUROFUSE Phase 2 Study Confirms Proof of Concept

Neuraptive Therapeutics, a leader in peripheral nerve treatment, has released promising 24-week data from the NEUROFUSE Study on NTX-001, reinforcing its safety and efficacy profile. The study, which is a multicenter, randomized, evaluator-blinded Phase 2a trial, highlights NTX-001's sustained safety and effectiveness as an adjunct treatment for severed peripheral nerves. The compound showed a significant improvement in hand function and pain reduction, as measured by the Michigan Hand Questionnaire and the Numerical Pain Rating Scale, respectively.

At the 24-week evaluation, NTX-001 maintained a favorable safety profile, with fewer treatment-emergent adverse events compared to standard care. The study's lead author, David M. Brogan, MD MSc, from Washington University in St. Louis, emphasized the potential of NTX-001 to enhance patient care for traumatic peripheral nerve injuries, which often lead to unsatisfactory outcomes and significant neuropathic pain.

Evan Tzanis, COO and EVP of R&D at Neuraptive Therapeutics, expressed enthusiasm about the study's findings and the company's plans to present the results at an upcoming scientific conference. He also mentioned the anticipation of an End of Phase 2 meeting with the FDA to discuss further development and the approval process.

Neuraptive Therapeutics is committed to developing innovative solutions for the large patient population affected by peripheral nerve injuries worldwide. The company focuses on addressing the complex challenges and unmet medical needs associated with nerve injuries.

The study's results build upon the proof of concept established by the 12-week data announced in January 2024, demonstrating consistent and supportive trends across multiple secondary endpoints, including sensory recovery assessments. The continued progress of NTX-001 positions Neuraptive Therapeutics at the cutting edge of nerve repair and regeneration technology.

Neuraptive Therapeutics, Inc. is dedicated to the innovation and development of medical products aimed at repairing and regenerating peripheral nerves. The company's mission is to meet the medical needs of patients and healthcare providers dealing with nerve injury challenges.